This three-day forum is the “must attend” event for those senior executives looking to drive-forward their medical affairs departments, develop superior evidence and enhance their KOL & stakeholder engagement at all levels.

Download agenda here for complete speaker list

Industry Experts

SVP, Head Worldwide Medical Affairs
GSK, UK

VP, Development Lead Cardiovascular
Bristol-Myers Squibb, USA

SVP Head Clinical Development
BTG International, UK

VP, Head of Region Europe Value Demonstration & Access
Shire International, Switzerland

Senior Director, Group Lead PEH HEOR Patient and Health Impact
Pfizer, USA

Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
Pfizer, USA

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

Senior Director, Medical Affairs – Oncology
Pierre Fabre, France

Executive Medical Director, Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

Lead, National Managed Care Liaisons
PACE (Patient Access Collaboration and Exchange)
Genentech, USA

Director of MSL Practices & External Engagement Lead
GSK, UK

Medical Scientific Liaison Group Leader
Roche, Italy

Medical Director
SLA Pharma, UK

National Director – Health Economics & Outcomes Research, Medical Affairs, Americas
Astellas, USA

Market Access Director
Medicines for Europe, Belgium

Chairman of the Board
Medical Science Liaison Society, USA


Senior Director, Global Scientific Affairs
Luminex Corporation, USA



Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

Director, Medical & Scientific Affairs
Karyopharm Therapeutics, USA

Non-Industry Stakeholders

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT) Patient Advocate, Belgium

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

Experienced Solution Providers

General Manager
Tardis Medical Consulting, UK

Corporate VP, Observational Research
PAREXEL

VP Heron Commercialization
PAREXEL

Director
PharmaReview, UK

 

Download agenda here for complete speaker list

Pictures from recent MedAffairs Leaders Forums. Imagine being there...

The first day will feature several keynote presentations from VP-Level thought leaders on shaping and leading the medical affairs departments, justifying medical affairs performance through innovative metrics and tracking effectiveness of the function as an essential element of today’s pharmaceutical companies. They will be discussing the strategic drivers for medical affairs, and guidance on how to make best use of this vital function.

Speaker List - Day 1

SVP, Head Worldwide Medical Affairs
GSK, UK

Senior Director, Medical Affairs – Oncology
Pierre Fabre, France

Senior Director, Group Lead PEH HEOR Patient and Health Impact
Pfizer, USA

Senior Director, Medical Affairs Lead - CV/Metabolism - Emerging Markets
Pfizer, USA

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT) Patient Advocate, Belgium

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

VP, Head of Region Europe Value Demonstration & Access
Shire International, Switzerland

VP, Development Lead Cardiovascular
Bristol-Myers Squibb, USA

SVP Head Clinical Development
BTG International, UK

Head Medical Affairs, Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

Senior Director, Global Scientific Affairs
Luminex Corporation, USA

Director
PharmaReview, UK

Increasing the sophistication of internal and external evidence development, to understand and enhance therapeutic value

Generating real world evidence via observational studies and the use of patient registries is one of the fastest growing areas of pharmaceutical R&D. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which demonstrates efficacy, safety and quality. The Medical Affairs unit plays a decisive role in generating this vital evidence and this stream will present solutions to the challenges companies face in generating high-quality evidence which will communicate a compelling value argument to all necessary stakeholders.

Speaker List - Stream 1

VP, Development Lead Cardiovascular
Bristol-Myers Squibb, USA

Executive Medical Director, Head of Medical Affairs for European Mid-Size Markets
Amgen, Austria

Alternate Patient member of the
EMA Committee on Advanced Therapies (CAT) Patient Advocate, Belgium

Corporate VP, Observational Research
PAREXEL

VP Heron Commercialization
PAREXEL

President
HealthCore, (an Anthem Inc. Company), USA

Medical Oncologist
The European Society for Medical Oncology (ESMO), Italy

 

Enhancing dialogue with physicians and patients to appreciate needs and provide extra value

Medical Affairs departments are increasingly looking to implement next generation medical communication practices, to offer essential evidence-based information to stakeholders on demand, through a variety of classical, yet also increasingly digital channels. This stream will focus on two key aspects of medical communication. Firstly, issues such as: protocol writing for internal late-phase studies and research initiatives; working with External Experts (KOLs) to enhance publications, abstracts & posters and receiving proposals for investigator-initiated studies. The second section of this day will focus on Medical Scientific Marketing communications, including the review process, compliance issues, ensuring the claims made by marketing colleagues are justified and appropriately communicated and also effectively localized from global-level to country-level market requirements.

Speaker List - Stream 2

Ambassador, Genetic Alliance, UK
Member, NHS England Rare Diseases Advisory Group

Lead, National Managed Care Liaisons
PACE (Patient Access Collaboration and Exchange)
Genentech, USA

Medical Director
SLA Pharma, UK

Market Access Director
Medicines for Europe, Belgium

Medical Affairs Director, World Business Line
Air Liquide Healthcare International, France

Director, Medical & Scientific Affairs
Karyopharm Therapeutics, USA

 

This day will feature best practice case studies on structuring, managing, and monitoring the evolving Medical Science Liaison role within your organisation. This meeting is an ideal chance to benchmark with other market leaders in this field who are utilising the unique MSL function to more effectively communicate with external experts, engage them with advanced science and demonstrate product evidence. All attending will discovery how MSLs can help regain the credibility of the pharmaceutical industry as a value-adding partner to the healthcare ecosystem.

Speaker List - Day 3

National Director – Health Economics & Outcomes Research, Medical Affairs, Americas
Astellas, USA

Director of MSL Practices & External Engagement Lead
GSK, UK

Chairman of the Board
Medical Science Liaison Society, USA

VP and Head of Medical Affairs EU/RoW
Jazz Pharmaceuticals, UK

Medical Scientific Liaison Group Leader
Roche, Italy

 

INTERACTIVE WORKSHOP

Your Workshop Leader:

Suzanna Lawrence
General Manager
Tardis Medical Consulting, UK

This event will provide all delegates the chance to meet one another through our many networking opportunities. With pre-event, mid-morning and mid-afternoon breaks as a standard, this event will also feature a complimentary networking dinner for all participants.

This evening will allow you to meet with our expert speaker panel who represent many stakeholder groups in a less formal setting. Our networking lunches will also allow you plenty of time to meet with your peers and colleagues whilst you refuel through the event.

This event will enable you to:
1. Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.
2. Discover which are the most intelligent ways to map and engage with KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.
3. Measure the performance of your medical affairs team and individuals.
4. Benchmark with experts to find out the best practices in late phase research, especially observational studies, patient registries and investigator initiated studies.
5. Discover how medical scientific liaisons, in support of commercial teams, are crucial to the communication of effectiveness, safety and cost effectiveness.
6. Learn how the medical affairs role can engage KOLs & enhance value for medical devices due to their unique product lifecycle and characteristics.

Who Will Benefit?

PHARMA & MEDICAL DEVICE: VPs, Directors & Managers of: Customer Relations, Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcomes & Liaison, Medical Communications, Marketing, KOL & Stakeholder Engagement, Late Phase & Real-World Research, Scientific Affairs, Medical Advisors and Patient-Centricity.

“NextLevel Pharma’s Medical Affairs meeting had two values for me: firstly, it allowed me to share best practices and try to learn what other companies are doing, which is great. Secondly, it was a fantastic networking opportunity, a lot of my peers are here which makes it special. I enjoyed the networking dinner as well, it was a nice walk, beautiful location and a very relaxed and casual atmosphere, NextLevel kept people communicating all the time – it was a fun night!”
Senior Director Medical Affairs Effectiveness, EMEA, Celgene

“I found this Medical Affairs meeting very interesting and beneficial, as I had the opportunity to take part in discussion of the important topics from different perspectives. I believe it was a great chance to meet other professionals and hear their presentations, which I think were very helpful.”
Global Medical Affairs Head, Chiesi Farmaceutici

“I really enjoyed the Medical Affairs Leaders Forum Congress in London. It offered an array of great speakers presenting on very relevant topics. I was able to gather important insights on Medical Affairs value and practical advice to bring back to my organization and use immediately. This meeting provided a variety of examples of organizational structure as well as sound recommendations on the scope of Medical Affairs.”
Senior Director, Global Medical Science Liaison, Philips Healthcare

“This experience was amazing, and its been for me a moment of great value to enhance myself and to relate with leading professionals in a global contest. I’m surely going home with an increased human and professional insight This is certainly the best event I could attend.”
Medical Science Liaison, Diabetes, Sanofi

“A thoughtfully organised event with a strong focus on the future direction and role of medical affairs in the pharmaceutical industry”
Medical Science Liaison, Norgine

“A value-added event with highly capable and inspiring speakers. I gathered many insights that will helpmy company to take the Medical Affairs function to the next level, and met some great new people in the networking sessions. All this was achieved in a friendly and inclusive atmosphere.”
Global Medical Affairs Director, Nutricia

“Thank you so much for making it possible to attend this wonderful and fantastic event in Berlin. It was a very nice experience for myself, and for sure I have found it very beneficial for my current and future business.”
Medical Manager & Oncology Clinical Research, Astrazeneca, Colombia

Event Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues